Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zhi-Quan Wu is active.

Publication


Featured researches published by Zhi-Quan Wu.


Journal of Cancer Research and Clinical Oncology | 2004

A decade’s studies on metastasis of hepatocellular carcinoma

Zhao-You Tang; Sheng-Long Ye; Liu Y; Lun-Xiu Qin; Hui-Chuan Sun; Qin-Hai Ye; Lu Wang; Jian Zhou; Shuang-Jian Qiu; Yan Li; Xue-Ning Ji; Hu Liu; Jing-Ling Xia; Zhi-Quan Wu; Jia Fan; Zeng-Chen Ma; Xin-Da Zhou; Zhi-Ying Lin; Kang-Da Liu

Metastasis remains one of the major challenges before hepatocellular carcinoma (HCC) is finally conquered. This paper summarized a decade’s studies on HCC metastasis at the Liver Cancer Institute of Fudan University. We have established a stepwise metastatic human HCC model system, which included a metastatic HCC model in nude mice (LCI-D20), a HCC cell line with high metastatic potential (MHCC97), a relatively low metastatic potential cell clone (MHCC97L) and several stepwise high metastatic potential cell clones (MHCC97H, HCCLM3, and HCCLM6) from their parent MHCC97 cell. Endeavors have been made for searching human HCC metastasis-related chromosomes/proteins/genes. Monogene-based studies revealed that HCC invasion/metastasis was similar to that of other solid tumors, and the biological characteristics of small HCC were only slightly better than that of large HCC. Using comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), genotyping, cDNA microarray, and 2-dimensional gel electrophoresis, we obtained some interesting results. In particular, in collaboration with the National Institute of Health (NIH) in the United States, we generated a molecular signature that can classify metastatic HCC patients, identified osteopontin as a lead gene in the signature, and found that genes favoring metastasis progression were initiated in the primary tumors. We also found that chromosome 8p deletion, particularly in the region of 8p23, was associated with HCC metastasis. Cytokeratin 19 was identified as one of the proteins, which was found in MHCC97H, but not in MHCC97L cells. Experimental interventions using the high metastatic nude mice model have provided clues for the prevention of HCC metastasis. Translation from workbench to bedside demonstrated that serum VEGF, microvessel density, and p53 scoring may be of value for the prediction of postoperative metastatic recurrence. Interferon alpha proved effective for the prevention of recurrence both experimentally and clinically. In conclusion, HCC metastasis that probably initiated in the primary tumor is a multigene-involved, multistep, and changing process. The further elucidation of the mechanism underlying HCC metastasis will provide a more solid basis for the prediction and prevention of the metastatic recurrence of HCC.


Clinical Cancer Research | 2008

Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection

Xin-Rong Yang; Yang Xu; Guo-Ming Shi; Jia Fan; Jian Zhou; Yuan Ji; Hui-Chuan Sun; Shuang-Jian Qiu; Bing Yu; Qiang Gao; Yi-Zhou He; Weng-Zhen Qin; Rong‐Xin Chen; Guo-Huan Yang; Bing Wu; Qing Lu; Zhi-Quan Wu; Zhao-You Tang

Purpose: Cytokeratin 10 (CK10) was found to be expressed differently in human hepatocellular carcinoma (HCC) cell lines with different metastatic potentials in our previous research. The aim of this study was to assess the value of CK10 alone or in combination with cytokeratin 19 (CK19) in predicting tumor recurrence after curative resection in HCC patients. Experimental Design: CK10 expression in stepwise metastatic HCC cell lines and tumor tissues from 50 HCC patients was investigated using immunofluorescence assay, quantitative real-time reverse transcription-PCR, and Western blot analyses. Tumor tissue microarrays of 300 HCC patients who underwent curative resection between 1997 and 2000 were used to detect the expressions of CK10 and CK19. Clinicopathologic data for these patients were evaluated. The prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests. Results: CK10 was overexpressed in the high metastatic HCC cell line and in tumor tissues of recurrent patients. Both univariate and multivariate analyses revealed that CK10 was a significant predictor for overall survival (OS) and disease-free survival, and that CK19 was a significant predictor for OS. CK10 expression was correlated with poor prognosis regardless of α-fetoprotein, tumor-node-metastasis stage, and vascular invasion. The 7-year OS and disease-free survival rates in CK10+ and/or CK19+ patients were 30.0% and 37.6%, respectively, which were significantly lower than that of CK10−/CK19− patients (56.1% and 60.0%, respectively; P < 0.001). Conclusion: CK10 is associated with HCC invasiveness. CK10 alone, or in combination with CK19, can be a novel predictor for poor prognosis of HCC patients after curative resection.


Journal of Cancer Research and Clinical Oncology | 2008

Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials.

Guo-Ming Shi; Yang Xu; Jia Fan; Jian Zhou; Xin-Rong Yang; Shuang-Jian Qiu; Yong Liao; Wei-Zhong Wu; Yuan Ji; Ai-Wu Ke; Zhen-Bin Ding; Yi-Zhou He; Bing Wu; Guo-Huan Yang; Wen-Zhen Qin; Wu Zhang; Jiang Zhu; Zhi-Hui Min; Zhi-Quan Wu


World Journal of Gastroenterology | 2003

Diagnosis and treatment of hepatic angiomyolipoma in 26 cases.

Ning Ren; Lun-Xiu Qin; Zhao-You Tang; Zhi-Quan Wu; Jia Fan


World Journal of Gastroenterology | 2006

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

Jian Zhou; Jia Fan; Zheng Wang; Zhi-Quan Wu; Shuang-Jian Qiu; Xiao-Wu Huang; Yao Yu; Jian Sun; Yong-Sheng Xiao; Yi-Feng He; Yu-Qi Wang; Zhao-You Tang


World Journal of Gastroenterology | 2005

Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis.

Jia Fan; Jian Zhou; Zhi-Quan Wu; Shuang-Jian Qiu; Xiao-Ying Wang; Ying-Hong Shi; Zhao-You Tang


World Journal of Gastroenterology | 2004

Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: Experience of 34 patients

Lun-Xiu Qin; Zeng-Chen Ma; Zhi-Quan Wu; Jia Fan; Xin-Da Zhou; Hui-Chuan Sun; Qing-Hai Ye; Lu Wang; Zhao-You Tang


World Journal of Gastroenterology | 2004

Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: A retrospective control study

Zheng-Gang Ren; Zhi-Ying Lin; Jinglin Xia; Sheng-Long Ye; Zeng-Chen Ma; Qing-Hai Ye; Lun-Xiu Qin; Zhi-Quan Wu; Jia Fan; Zhao-You Tang


World Journal of Gastroenterology | 2002

P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection

Lun-Xiu Qin; Zhao-You Tang; Zeng-Chen Ma; Zhi-Quan Wu; Xin-Da Zhou; Qing-Hai Ye; Yuan Ji; Liwen Huang; Hu-Liang Jia; Hui-Chuan Sun; Lu Wang


World Journal of Gastroenterology | 2001

Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential.

Zhao-You Tang; Fan-Xian Sun; Jian Tian; Sheng-Long Ye; Yin-Kun Liu; Kang-Da Liu; Qiong Xue; Jie Chen; Jinglin Xia; Lun-Xiu Qin; Hui-Chuan Sun; Lu Wang; Jian Zhou; Yan Li; Zeng-Chen Ma; Xin-Da Zhou; Zhi-Quan Wu; Zhi-Ying Lin; Bing-Hui Yang

Collaboration


Dive into the Zhi-Quan Wu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Zeng-Chen Ma

Fudan University Shanghai Medical College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Xin-Da Zhou

Fudan University Shanghai Medical College

View shared research outputs
Top Co-Authors

Avatar

Yuan Ji

NorthShore University HealthSystem

View shared research outputs
Researchain Logo
Decentralizing Knowledge